Heart failure & cardiomyopathies

Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study

Eur Heart JPublished Prospective registry and cohort study

Authors' conclusion

Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement > 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy.

Study context

Population
Patients with de novo heart failure with reduced ejection fraction (HFrEF) and left ventricular ejection fraction (LVEF) ≤ 35% prescribed a wearable cardioverter-defibrillator, 2017–2022entered study phase
Participants
598 patients
Outcome
LVEF improvement > 35% after guideline-recommended medical therapy initiation; percentage of target dose reached
Follow-up
Days 90 and 180
Methodological detailsmulticentre, 68 sites, registry phase 3 months then study phase up to 1 year
  • Multicentre
  • 68 sites
  • Registry phase 3 months then study phase up to 1 year

Main finding

As reported in the abstract

LVEF improvement > 35%
LVEF improvement > 35% at Day 90
46% (95% CI 41%-50%)
LVEF improvement > 35% by Day 180 among those with persistently low LVEF at Day 90
46% (95% CI 40%-52%)
Total LVEF improvement > 35% by Day 180
68% (95% CI 63%-72%)
Significant increase in dosage of beta-blockers, renin-angiotensin system inhibitors and MRA during first 180 days
P < .001

Observational data: associations, not effects.

Further findings

LVEF improvement > 35% at 360 days

Improvement > 35% in 392 patients followed for 360 days
77% (95% CI 72%-81%)

Safety

Sustained ventricular tachyarrhythmias in WCD carriers · Until Day 90

Sustained ventricular tachyarrhythmias until Day 90
24 (1.8%)
No sustained ventricular tachyarrhythmia after 90 days

Original publication

Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study. Eur Heart J. Published 12 June 2024. doi:10.1093/eurheartj/ehae334

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.